CURRICULUM VITAE - SYNOPSIS
`
`
`
`
`
`Studies of Chemistry at the University of Karlsruhe
`(Germany) with graduation as Dipl. Chemiker
`Doctoral thesis at the Department of
`Biochemistry, Faculty of Chemistry, University of
`Karlsruhe on the mechanisms of protein biosynthesis
`Degree of Dr. rer. nat. by the University of Karlsruhe.
`
`Research Scientist at Behringwerke AG in the field of
`haemostaseology and protein biochemistry
`Manager and Assoc. Director in Preclinical R&D at
`Centeon Pharma GmbH and at Aventis Behring
`GmbH
`Assoc. Director in Preclinical R&D at CSL Behring
`GmbH
`Director Process Development, Preclinical R&D at
`CSL Behring GmbH
`
`Dr. rer. nat. Hubert J. Metzner
`Director Process Development
`Recombinant Product Development
`CSL Behring GmbH
`Emil-von-Behring Str. 76
`D-35041 Marburg
`
`
`
`Education:
`
`1977 - 1983:
`
`1983 - 1987:
`
`
`1988:
`
`
`
`Occupational Career:
`
`Sept. 1988 - June 1995:
`
`July 1995 – April 2004:
`
`April 2004 – September 2007:
`
`Since October 2007:
`
`
`
`
`
`Fields of Interest:
`
`Coagulation and fibrinolysis, clotting factors and related products, haemophilia treatments;
`protein biochemistry, development of plasma-derived and recombinant protein therapeutics.
`
`CSL EXHIBIT 1017
`CSL v. Shire
`
`Page 1 of 4
`
`

`

`Selected Publications/Abstracts
`
` -
`
` R. Hilgenfeld, A. Liesum, R. Storm, H.J. Metzner, H.E. Karges
` Crystallization of Blood Coagulation Factor XIII by an automated
` procedure
` FEBS Lett. 265 (1,2), 110-112 (90)
`
` -
`
` H.J. Metzner, K. Funk, U. Panzer, E.P. Pâques
` Recombinant factor XIII - biochemical properties
` in "Factor XIII: Second International Conference Marburg",
` ed. J. McDonagh, R. Seitz, R. Egbring, 87-93 (1993) Schattauer
`
` -
`
` R. Hilgenfeld, A. Liesum, D. Mausil, H.J. Metzner, H.E. Karges
` Towards a high-resolution crystal Structure of the factor XIII a-
` chain dimer
` in "Factor XIII: Second International Conference Marburg",
` ed. J. McDonagh, R. Seitz, R. Egbring, 106-109 (1993) Schattauer
`
` -
`
` P. Hermentin, R. Witzel, E.-J. Kanzy, G. Diderrich, D. Hoffmann,
` H. Metzner, J. Vorlop, and H. Haupt:
` The hypothetical N-glycan charge: a number that characterizes
` protein glycosylation
` Glycobiology 6, 217-230 (1996)
`
` -
`
` H.E. Karges and H.J. Metzner
` Therapeutic factor XIII preparations and perspectives for recombinant factor XIII
` Sem Throm Hem 22: 427-436 (1996)
`
` -
`
` H.J. Metzner, B. Watzka, H.-G. Müller, U. Klockmann, P. Hermentin, R. Höinghaus and G.
` Auerswald
` Stability of factor VIII concentrates - a precondition for continuous infusion
` Biomed Progr 10: 31-34 (1997)
`
` -
`
` -
`
` M.S. Weiss, H. J. Metzner and R. Hilgenfeld
` Two non-proline cis peptide bonds may be important for factor XIII function
` FEBS Letters 423: 291-296 (1998)
`
` H.J. Metzner, P. Hermentin, T. Cuesta-Linker, S. Langner, H.-G. Müller and J. Friedebold
` Characterization of factor VIII/von Willebrand factor concentrates using a modified method
`of von
` Willebrand factor multimer analysis (Abstract, ASH-Meeting)
` Blood 92, No. 10 (Suppl. 1), 49a (1998)
`
` -
`
` H.J. Metzner, P. Hermentin, T. Cuesta-Linker, S. Langner, H.-G. Müller and J. Friedebold
` Characterization of factor VIII/von Willebrand factor concentrates using a modified method
`of von
` Willebrand factor multimer analysis
` Haemophilia 4 (Suppl. 3): 25-32 (1998)
`
` -
`
` H.J. Metzner, G. Dickneite and K.-H. Diehl
`
`Page 2 of 4
`
`

`

`Faktor XIII und Wundheilung – präklinische Untersuchungen
`In: Klinische Aspekte des Faktor XIII-Mangels. Diagnostik, klinische Relevanz, klinische
`Forschung
`Eds. R. Egbring, R. Seitz, G. Wozniak
`Karger, 1999, pp 111-118
`
` -
`
` T. Noll, G. Wozniak, K. McCarson, A. Hajimohammad, H.J. Metzner, J. Inserte, W.
`Kummer, F.W. Hehrlein and H.M. Piper
`Effect of factor XIII on endothelial barrier function
`J Exp Med 189 (9): 1373-1382 (1999)
`
`- G. Dickneite, H. Metzner and U. Nicolay
`Prevention of suture hole bleeding using fibrin sealant: Benefits of factor XIII
`J Surg Res 93: 201-205 (2000)
`
` H.J. Metzner, K. Funk, H. Naumann, A. Eisberg, J. Müller-Cohrs, and G. Witzke
` A new method to investigate the adhesive properties of fibrin sealant preparations in vitro
` Blood 98 (11, Part 2): 75b (2001)
`
` -
`
` -
`
` G. Dickneite, H.J. Metzner, M. Kroez, B. Hein und U. Nicolay
` The importance of Factor XIII as a component of fibrin sealants
` J Surg Res 107: 186-195 (2002)
`
` -
`
` P. Lauer, H.J. Metzner, G. Zettlmeißl, M. Li, A.G. Smith, R. Lathe und G. Dickneite
` Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: Hemostatic
` abnormalities in mutant mice and characterization of the coagulation deficit
` Thromb Haemost 88: 967-974 (2002)
`
` -
`
` H.J. Metzner, H. Naumann, and G. Witzke
` Comparison of the Fibrinogen Components of Commercial Fibrin Sealants: Biochemical
` Parameters
` Ann Hematol 82 (Suppl 1): S62 (2003)
` (Abstract)
`
`- G. Dickneite, H.J. Metzner, M. Kroez, U. Nicolay
` Benefits of factor XIII as a component of fibrin sealants: Experimental surgery
` Biomed Progr 16 (Suppl. 1): 6-13 (2003)
`
` -
`
` M. Phillips, G. Dickneite, H. Metzner
` Fibrin sealants in supporting surgical techniques: strength in factor XIII
` Cardiovasc Surg 11: 13-16 (2003)
`
` -
`
` G. Dickneite, H. Metzner, T. Pfeifer, M. Kroez, G. Witzke
`A comparison of fibrin sealants in relation to their in vitro and in vivo properties
`Thromb Res 112: 73-82 (2003)
`
` -
`
` H. J. Metzner, E.-J. Kanzy, A. Kalbass, H. Lind, H.-G. Müller, G. Kumpe, S. Schulte
`Analytical characterization of infusion volume reduced Humate-P/Haemate P
`Blood 106(11): 122b (2005)
`ASH Abstract 2005
`
`Page 3 of 4
`
`

`

` -
`
` U. Budde, H.J. Metzner, H.-G. Müller
`Comparative analysis and classification of von Willebrand factor/factor VIII concentrates:
`Impact on treatment of patients with von Willebrand disease
`Semin Thromb Hemost 32: 626-635 (2006)
`
` HJ Metzner, T. Weimer, U. Kronthaler, W. Lang, S. Schulte
`Genetic fusion to albumin improves the pharmacokinetic properties of factor IX
`Thromb Haemost 102: 634-644 (2009)
`
` -
`
` -
`
` Jámbor C., Reul V., Schnider T.W., Degiacomi P., Metzner H., Korte W.C.
`In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases
`fibrinolytic effects in whole blood
`Anesthesia & Analgesia 109: 1023-1028 (2009)
`
` -
`
` H.J. Metzner, T. Weimer, and S. Schulte
`Half-life extension by fusion to recombinant albumin
`In: Therapeutic Proteins
`Ed. R. Kontermann
`Wiley-Blackwell, 2012, pp 223-247
`
` -
`
` T. Weimer, H.J. Metzner, and S. Schulte
`Recombinant albumin fusion proteins
`In: Fusion Protein Technologies for Biopharmaceuticals – Applications and Challenges
`Ed. S.R. Schmidt
`John Wiley & Sons, 2013, pp 163-178
`
` -
`
` S.B. Zollner, E. Raquet, J. Müller-Cohrs, H.J. Metzner, T. Weimer, I. Pragst, G. Dickneite,
` S. Schulte
` Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-
`chain
` factor VIII.
`Thromb Res. 2013; 132(2): 280-287
`
` -
`
` HJ Metzner, S. Pipe, T. Weimer, S. Schulte
`Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant
`albumin
`Thromb Haemost 110: 931-939 (2013)
`
`- S. Zollner, E. Raquet, P. Claar, J. Müller-Cohrs, H.J. Metzner, T. Weimer, I. Pragst, G.
`Dickneite,
` S. Schulte
` Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel
`recombinant single-chain factor VIII.
`Thromb Res. 2014; 134: 125-131
`
`- S. Schmidbauer, R. Witzel, L. Robbel, P. Sebastian, N. Grammel, H.J. Metzner, and S.
`Schulte
` Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain
`factor VIII. Thromb Res. 2015; 136: 388-395
`
`Page 4 of 4
`
`